NPS MedicineWise is an independent, notfor-profit evidence-based organisation. We provide practical tools, information and continuing professional education to improve the way health technologies, medicines and medical tests are prescribed and used.
NPS MedicineWise works across Australia and the Asia-Pacific to positively change the attitudes and behaviours which exist around the use of medicines and medical tests, so that consumers and health professionals are equipped to make the best decisions when it counts.
Study methods
This study consisted of three phases:
Phase 1: Data sourced from RCT's were extracted to two meta-analyses examining the risk of fall and stroke (and cardiovascular adverse events(CVAE)) following use of atypical antipsychotics (Quetiapine, Risperidone and Olanzapine) among dementia patients.
Phase 2: The effectiveness of the antipsychotics program was assessed using data from the NPS clinical audit, general practitioner survey and interrupted time series analyses of administrative data from the Australian Pharmaceutical Benefits Scheme (PBS).
Phase 3: A cost-benefit analysis was conducted to assess the impact of the program in reducing adverse events: stroke /CVAE incidence and related hospitalisations due to changes in antipsychotics prescribing attributable to the program. This was performed by developing a decision tree using TreeAge Pro software. Data from phase 1 and 2 were used to develop the model.
Objectives
In 2011, NPS MedicineWise Australia developed and implemented a multi-faceted academic detailing program: "Balancing benefits and harms of antipsychotic therapy" to improve general medical practitioner (GP) prescribing of antipsychotic therapy. A significant component of this program focussed on reducing antipsychotics inappropriately prescribed to elderly patients with dementia.
Evidence has demonstrated that older adults are prescribed antipsychotics for the management of their dementia symptoms despite modest efficacy and safety of antipsychotic therapy in treating dementia.
This study is an economic evaluation of the NPS MedicineWise educational program messages in terms of reduced stroke incidence due to reduction in antipsychotic prescribing including Olanzapine, Quetiapine and Risperidone
Results
Phase 1: A total of 36 falls related studies and 39 stroke/CVAE related studies were identified with only six and ten studies included respectively.
Pooled results of falls data indicated that the odds ratio of a fall event was not statistically significant. The results of the stroke/CVAE related studies indicated that the odds ratio of a stroke event or CVAE occurring was 1.67 higher in atypical antipsychotic users compared to non-users (95% CI: 1.26-2.21) (Figure 1 ).
Phase 2 41% of GP Australia wide participated in the program. Changes in GP prescribing practice, attributable to the NPS MedicineWise program, were associated with a decrease of 72,384 prescriptions, or a relative 7.3% reduction in modelled PBS prescription volume. It is estimated that the NPS MedicineWise program reduced government expenditure on antipsychotics in adults over 70 years of age, for the 2011-14 financial years, by $4.27 million.
Phase 3
The NPS MedicineWise program was found to be cost effective compared with standard practice. The incremental cost-effectiveness ratio for the NPS program compared with standard practice were AUD$52,225 per 0.01 Stroke/CVAE avoided. The model suggests that 177 stroke /CVAE were avoided as a result of the NPS MedicineWise program. 
Conclusions
This is a comprehensive economic analysis conducted in Australia to have utilised PBS data and large scale evaluation results to examine interventions focusing on the appropriate use of medicines in older adults. The results will be used to further inform future public health interventions aimed at managing the health outcomes of this vulnerable and growing population. 
